Unknown

Dataset Information

0

Improved anti-glioblastoma efficacy by IL-13Rα2 mediated copolymer nanoparticles loaded with paclitaxel.


ABSTRACT: Glioma presents one of the most malignant brain tumors, and the therapeutic effect is often limited due to the existence of brain tumor barrier. Based on interleukin-13 receptor α2 (IL-13Rα2) over-expression on glioma cell, it was demonstrated to be a potential receptor for glioma targeting. In this study, Pep-1-conjugated PEGylated nanoparticles loaded with paclitaxel (Pep-NP-PTX) were developed as a targeting drug delivery system for glioma treatment. The Pep-NP-PTX presented satisfactory size of 95.78 nm with narrow size distribution. Compared with NP-PTX, Pep-NP-PTX exhibited significantly enhanced cellular uptake in C6 cells (p < 0.001). The in vitro anti-proliferation evaluation showed that the IC50 were 146 ng/ml and 349 ng/ml of Pep-NP-PTX and NP-PTX, respectively. The in vivo fluorescent image results indicated that Pep-NP had higher specificity and efficiency in intracranial tumor accumulation. Following intravenous administration, Pep-NP-PTX could enhance the distribution of PTX in vivo glioma section, 1.98, 1.91 and 1.53-fold over that of NP-PTX group after 0.5, 1 and 4 h, respectively. Pep-NP-PTX could improve the anti-glioma efficacy with a median survival time of 32 days, which was significantly longer than that of PTX-NP (23 days) and Taxol(®) (22 days). In conclusion, Pep-NP-PTX is a potential targeting drug delivery system for glioma treatment.

SUBMITTER: Wang B 

PROVIDER: S-EPMC4645113 | BioStudies | 2015-01-01

SECONDARY ACCESSION(S): 10.1038/srep16589

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC6136913 | BioStudies
2020-01-01 | S-EPMC7426108 | BioStudies
2018-01-01 | S-EPMC6389131 | BioStudies
1000-01-01 | S-EPMC5529082 | BioStudies
2018-01-01 | S-EPMC6251464 | BioStudies
2011-01-01 | S-EPMC3092917 | BioStudies
1000-01-01 | S-EPMC6171435 | BioStudies
2000-01-01 | S-EPMC1572461 | BioStudies
2015-01-01 | S-EPMC4456265 | BioStudies
2020-01-01 | S-EPMC7086363 | BioStudies